Home > News > 100/Vectorcardiographic direction of ventricular activation as a predictor of long-term outcomes after cardiac resynchronisation therapy
Arrhythmia
Read Time: 2 mins

100/Vectorcardiographic direction of ventricular activation as a predictor of long-term outcomes after cardiac resynchronisation therapy

Published Online: October 3rd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr100
Authors: O Okafor (Presenting Author) - Aston University, Birmingham, UK; PM van Dam - University Medical Centre, Utrecht, The Netherlands; A Zegard - Aston University, Birmingham, UK; B Stegemann - Aston University, Birmingham, UK; T Qiu - Queen Elizabeth Hospital, Birmingham, UK; H Marshall - Queen Elizabeth Hospital, Birmingham, UK; F Leyva - Aston University, Birmingham, UK
Quick Links:
Article
Article Information
Article:

Background: Predicting clinical outcomes after cardiac resynchronisation therapy (CRT) remains a challenge. Although QRS duration is crucial as an indication for CRT, it is a poor predictor of clinical outcomes.
Objectives: To determine whether the direction of ventricular activation, measured using the ratio of the temporospatial isochrone to QRS duration (TSIQRSd) on vectorcardiography (VCG) predicts clinical outcomes
after CRT.
Methods: In this retrospective study, TSIQRSd, QRS area, QRS duration (QRSd) and QRS morphology (LBBB), derived from pre-implantation ECGs, were assessed in relation to the primary endpoint of cardiac mortality
after CRT.
Results: In patients (n=720, age 72.8 ± 11.8 years, 71.3% male) undergoing CRT over 7.7 years (median follow-up period of 3.7 [interquartile range 2.3–5.1] years), TSIQRSd <92% predicted cardiac mortality (adjusted hazard
ratio [aHR]: 2.21, 95% CI 1.54–3.17; p<0.001), independent of known confounders. When considered together with QRSd, LBBB and QRS area, TSIQRSd <92% was the only predictor of cardiac mortality (aHR: 2.22, 95% CI 1.55–3.18; c-statistics: 0.59, 0.57, 0.63 and 0.68, respectively). A TSIQRSd < 92% predicted cardiac mortality in the strata of QRSd (< or ≥150 ms) and QRS morphology (LBBB or non-LBBB) (all p<0.0001). Both TSIQRSd <92% and a QRS area <102 ms also predicted total mortality or heart failure hospitalisation, and total mortality or major adverse cardiac events (all p<0.001)
Conclusions: Vectorcardiographic TSIQRSd is superior to QRS area, QRSd and QRS morphology in predicting cardiac mortality after CRT. These findings support the use of pre-implantation VCG in predicting clinical outcomes after CRT.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
Arrhythmia
43/Cardiac tamponade as a complication of transseptal puncture: associations and operatordependent variables during left atrial ablation at Barts Heart Centre
E Maclean (Presenting Author) - St Bartholomew’s Hospital, London; K Mahtani - St Bartholomew’s Hospital, London; C Butcher - St Bartholomew’s Hospital, London; N Ahluwalia - St Bartholomew’s Hospital, London; M Finlay - St Bartholomew’s Hospital, London; S Honarbakhsh - St Bartholomew’s Hospital, London; A Creta - St Bartholomew’s Hospital, London; A Chow - St Bartholomew’s Hospital, London; V Sawhney - St Bartholomew’s Hospital, London; V Ezzat - St Bartholomew’s Hospital, London; MJ Earley - St Bartholomew’s Hospital, London; M Dhinoja - St Bartholomew’s Hospital, London; S Sporton - St Bartholomew’s Hospital, London; MD Lowe - St Bartholomew’s Hospital, London; PD Lambiase - St Bartholomew’s Hospital, London; F Khan - St Bartholomew’s Hospital, London; SY Ahsan - St Bartholomew’s Hospital, London; RJ Hunter - St Bartholomew’s Hospital, London; RJ Schilling - St Bartholomew’s Hospital, London; O Sega - St Bartholomew’s Hospital, London Read Time: 2 mins

European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr43

Introduction: Cardiac tamponade is a high morbidity complication of transseptal puncture (TSP). We examined the incidence and predictors of TSP-related cardiac tamponade (TRCT) for all patients undergoing left atrial ablation at our centre from 2016-2020. Methods: Patient and procedural variables were extracted retrospectively. Cases of cardiac tamponade were scrutinised to adjudicate TSP culpability. Adjusted multivariate […]

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72